(Tos-GPR)2-[Rh110]

(Tos-GPR)2-[Rh110]

  • Description

  • Application Data

Description

Fluorogenic subtrate for thrombin. This non-fluorescent substrate is cleaved by thrombin in 2 successive steps to release Rhodamine 110 and thus allow fluorescence

See full description

Application Data

Catalogue number crb1100251
Molecular Weight 1259.42
Sequence (one letter code)

(Tos-GPR)2-[Rh110]

Sequence (three letter code)

[p-tosyl]-Gly-Pro-Arg-[Rhodamine 110]-Arg-Pro-Gly-[p-tosyl]

Aliase (Tos-GPR)2-[R110]
Modifications where Tos is p-tosyl, where Rh110 is Rhodamine 110
Purity >95%
References

Jaclyn et al., (2020). Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer’s Disease. Front Neurosci. 14: 762. PMID: 32792902

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

Fluorogenic substrate for thrombin that when in its intact state does not fluoresce, however upon cleavage by thrombin in 2 successive steps, Rhodamine 110 is released to allow fluorescence.

Thrombin is a multifunctional serine protease and is the principal enzyme of hemostasis. It catalyzes the conversion of fibrinogen to fibrin and activates procoagulant factors V, VIII, XI, and XIII. When bound to thrombomodulin, it activates protein C, an anticoagulant zymogen. Thrombin also activates platelets, regulates endothelial cell function, and has a host of direct actions on other cells.

Thrombin has been found to act as a mediator of vascular dysfunction and inflammation in both the peripheral and the central nervous systems. Thrombin contributes to the development of cardiovascular disease, atherosclerosis and diabetes and promotes vascular dysfunction, inflammation, and neurodegeneration. Thrombin is elevated in the brains of people with Alzheimer’s disease (AD) and therefore may be a therapeutic target in AD.

(Tos-GPR)2-[Rh110]

Cat No.Pack SizePriceQty.
1mg£220.00
0.5mg£170.00
Bulk Quote

Download Family PDF